November 28, 2019
ASKA Pharmaceutical said on November 26 that ulipristal (development code: CDB-2914), which is in development as a hysteromyoma treatment, met its primary endpoint in a Japan PIII trial that compared its efficacy and safety to the injectable gonadotropin-releasing hormone (GnRH)...read more